New Study Predicts $350 Billion U.S. Pharmacy Industry by 2015, Identifies Risks to Profitability

Today Pembroke Consulting released the U.S. Pharmacy Industry: 2009 Economic Report and Outlook, a comprehensive analysis of the U.S. pharmacy and drugstore industry. This new research report is among the first to analyze the economics of the pharmacy industry and project the industry's future growth. It also identifies the seven most important trends affecting future profitability, and projects future growth rates for all major industry segments.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Total prescriptions revenues of U.S. pharmacies and drugstores will reach more than $350 billion by 2015, an increase of almost $100 billion from 2008

Philadelphia, PA (PRWEB) September 30, 2009

Today Pembroke Consulting released the U.S. Pharmacy Industry: 2009 Economic Report and Outlook, a comprehensive analysis of the U.S. pharmacy and drugstore industry. This new research report is among the first to analyze the economics of the pharmacy industry and project the industry's future growth. It also identifies the seven most important trends affecting future profitability, and projects future growth rates for all major industry segments.

"Total prescriptions revenues of U.S. pharmacies and drugstores will reach more than $350 billion by 2015, an increase of almost $100 billion from 2008," said Pembroke Consulting President Adam J. Fein, Ph.D., the study's author and an expert on pharmacy economics and the pharmaceutical supply chain. "Generic drugs will soon be more than 80% of U.S. prescriptions, slowing pharmacies' revenue growth. But expensive specialty pharmaceuticals will grow to be at least 30% of total pharmacy revenues, adding to revenue growth."

The report estimates that generic drugs contributed $13 billion more in gross profits to pharmacies than brand drugs did in 2008. This superior profitability will be threatened in coming years as healthcare payers implement new payment benchmarks and pharmacies engage in a generic prescription price war.

"Although the coming wave of generic drugs will add to pharmacies' profits, channel margins will increasingly be seen as a mechanism to reduce U.S. drug spending," Fein noted. "The use of novel contracting strategies such as cost-plus reimbursement will accelerate."

To download the U.S. Pharmacy Industry: 2009 Economic Report and Outlook report, please visit http://www.pembrokeconsulting.com/pharmacy.html.

Pembroke Consulting is a management advisory and business research firm that helps executives improve strategic and tactical decision making. To learn more about its services visit http://www.PembrokeConsulting.com.

###


Contact